newsfilter
← Latest News
GlobeNewswire·

Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates

- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis P